PT3107559T - Regime posológico de composto de fgf-18 - Google Patents

Regime posológico de composto de fgf-18

Info

Publication number
PT3107559T
PT3107559T PT15706006T PT15706006T PT3107559T PT 3107559 T PT3107559 T PT 3107559T PT 15706006 T PT15706006 T PT 15706006T PT 15706006 T PT15706006 T PT 15706006T PT 3107559 T PT3107559 T PT 3107559T
Authority
PT
Portugal
Prior art keywords
fgf
dosing regimen
compound dosing
compound
regimen
Prior art date
Application number
PT15706006T
Other languages
English (en)
Portuguese (pt)
Inventor
H Ladel Christoph
Guehring Hans
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of PT3107559T publication Critical patent/PT3107559T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/1825Fibroblast growth factor [FGF]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/50Fibroblast growth factor [FGF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/20Interleukins [IL]
    • A61K38/2006IL-1
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT15706006T 2014-02-20 2015-02-20 Regime posológico de composto de fgf-18 PT3107559T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14000600 2014-02-20

Publications (1)

Publication Number Publication Date
PT3107559T true PT3107559T (pt) 2018-10-31

Family

ID=50151088

Family Applications (2)

Application Number Title Priority Date Filing Date
PT15706006T PT3107559T (pt) 2014-02-20 2015-02-20 Regime posológico de composto de fgf-18
PT15707076T PT3119417T (pt) 2014-02-20 2015-02-20 Regime posológico de composto de fgf-18

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT15707076T PT3119417T (pt) 2014-02-20 2015-02-20 Regime posológico de composto de fgf-18

Country Status (25)

Country Link
US (2) US9724388B2 (https=)
EP (2) EP3119417B1 (https=)
JP (2) JP6431082B2 (https=)
KR (2) KR102410988B1 (https=)
CN (2) CN106456713A (https=)
AR (2) AR099558A1 (https=)
AU (2) AU2015220773B2 (https=)
BR (2) BR112016018696A2 (https=)
CA (1) CA2938791A1 (https=)
DK (2) DK3107559T3 (https=)
ES (2) ES2689071T3 (https=)
HR (2) HRP20181570T1 (https=)
HU (1) HUE040350T2 (https=)
IL (2) IL247084B (https=)
LT (2) LT3107559T (https=)
MX (2) MX2016010871A (https=)
NZ (1) NZ723148A (https=)
PL (2) PL3107559T3 (https=)
PT (2) PT3107559T (https=)
RS (2) RS57853B1 (https=)
RU (2) RU2691946C2 (https=)
SG (2) SG11201606502YA (https=)
SI (2) SI3107559T1 (https=)
WO (2) WO2015124727A1 (https=)
ZA (2) ZA201605547B (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6510547B2 (ja) 2014-02-20 2019-05-08 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung Fgf−18を含むインプラント
HUE040350T2 (hu) 2014-02-20 2019-03-28 Merck Patent Gmbh FGF-18 vegyületadagoló étrend
AU2016211950A1 (en) 2015-01-29 2017-07-13 Ares Trading S.A. Immunoassays for high positively charged proteins
MX384205B (es) 2016-02-22 2025-03-14 Novartis Ag Metodos para usar agonistas de fxr.
IL273613B2 (en) 2017-09-29 2026-02-01 Merck Patent Gmbh Metabolic biomarkers for predicting response to FGF-18 compound
SI3688468T1 (sl) 2017-09-29 2022-08-31 Merck Patent Gmbh Vnetni biomarkerji za predvidevanje odzivov na spojino FGF-18
IL281333B2 (en) 2018-09-10 2025-11-01 Merck Patent Gmbh A method for reducing risk in a clinical trial
JP7671249B2 (ja) * 2019-02-08 2025-05-01 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 変形性関節症が急速に進行するリスクがある患者の治療
KR102920449B1 (ko) * 2023-03-29 2026-02-03 주식회사 아이프로테인테라퓨틱스 인터류킨-1 수용체 길항제 변이체 및 이의 용도
WO2025077768A1 (en) * 2023-10-11 2025-04-17 Sichuan Real & Best Biotech Co., Ltd. Compositions and methods for treating arthritis

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2493840T3 (es) * 2002-10-07 2014-09-12 Zymogenetics, Inc. Procedimiento de administración de FGF-18
ES2706848T3 (es) * 2004-07-06 2019-04-01 Zymogenetics Inc Composición farmacéutica que comprende FGF18 y antagonista de IL-1 y método de uso
US20070243132A1 (en) * 2005-12-22 2007-10-18 Apollo Life Sciences Limited Transdermal delivery of pharmaceutical agents
MY148277A (en) * 2006-08-25 2013-03-29 Ares Trading Sa Treatment of cartilage disorders with fgf-18
HRP20120643T1 (hr) 2006-08-25 2012-08-31 Ares Trading S.A. Liječenje poremećaja hrskavice sa fgf-18
DE102006043260A1 (de) * 2006-09-11 2008-03-27 Krones Ag Etikettieranlage
CN103547580B (zh) * 2011-03-22 2016-12-07 阿迪维纳斯疗法有限公司 取代的稠合三环化合物、其组合物及医药用途
JP6510547B2 (ja) 2014-02-20 2019-05-08 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung Fgf−18を含むインプラント
HUE040350T2 (hu) 2014-02-20 2019-03-28 Merck Patent Gmbh FGF-18 vegyületadagoló étrend
MX2016010873A (es) 2014-02-20 2016-11-17 Merck Patent Gmbh Factor de crecimiento de fibroblastos 18 en los procedimientos para el trasplante de injertos y para ingenieria de tejidos.

Also Published As

Publication number Publication date
CN106456713A (zh) 2017-02-22
ES2689071T3 (es) 2018-11-08
RU2700582C2 (ru) 2019-09-18
JP6431083B2 (ja) 2018-11-28
EP3107559A1 (en) 2016-12-28
EP3119417B1 (en) 2018-07-11
HRP20181570T1 (hr) 2018-11-30
AR099558A1 (es) 2016-08-03
RS57709B1 (sr) 2018-12-31
ZA201605548B (en) 2018-12-19
ZA201605547B (en) 2019-09-25
BR112016018685A2 (pt) 2017-10-17
SI3119417T1 (sl) 2018-11-30
AU2015220773A1 (en) 2016-09-01
ES2688551T3 (es) 2018-11-05
SI3107559T1 (sl) 2018-11-30
IL247083B (en) 2019-09-26
US9724388B2 (en) 2017-08-08
JP2017512194A (ja) 2017-05-18
WO2015124727A1 (en) 2015-08-27
AU2015220773B2 (en) 2020-10-08
WO2015124731A1 (en) 2015-08-27
LT3107559T (lt) 2018-10-25
PL3107559T3 (pl) 2019-01-31
JP6431082B2 (ja) 2018-11-28
HRP20181572T1 (hr) 2018-11-30
PL3119417T3 (pl) 2019-01-31
AU2015220777B2 (en) 2020-10-22
IL247083A0 (en) 2016-09-29
PT3119417T (pt) 2018-10-31
SG11201606502YA (en) 2016-09-29
CN106232622A (zh) 2016-12-14
KR20160116000A (ko) 2016-10-06
BR112016018696A2 (pt) 2017-10-17
KR102410988B1 (ko) 2022-06-17
AU2015220777A1 (en) 2016-09-01
US9889179B2 (en) 2018-02-13
US20170072017A1 (en) 2017-03-16
CA2938791A1 (en) 2015-08-27
NZ723148A (en) 2022-08-26
NZ723139A (en) 2022-12-23
LT3119417T (lt) 2018-10-25
MX2016010871A (es) 2016-11-17
KR20160116001A (ko) 2016-10-06
US20170056474A1 (en) 2017-03-02
DK3119417T3 (en) 2018-10-22
RS57853B1 (sr) 2018-12-31
HUE040350T2 (hu) 2019-03-28
AR099510A1 (es) 2016-07-27
IL247084B (en) 2019-09-26
MX2016010872A (es) 2016-11-17
CA2938793A1 (en) 2015-08-27
EP3107559B1 (en) 2018-07-11
RU2691946C2 (ru) 2019-06-19
DK3107559T3 (en) 2018-10-15
RU2016137292A (ru) 2018-03-21
IL247084A0 (en) 2016-09-29
JP2017507142A (ja) 2017-03-16
EP3119417A1 (en) 2017-01-25
SG11201606505UA (en) 2016-09-29
RU2016137292A3 (https=) 2018-09-17
KR102410986B1 (ko) 2022-06-17
RU2016137289A3 (https=) 2018-10-19
RU2016137289A (ru) 2018-03-21

Similar Documents

Publication Publication Date Title
ES3064846T3 (en) Tau-binding antibodies
GB2544029B (en) Packages
ZA201605548B (en) Fgf-18 compound dosing regimen
GB201508180D0 (en) Antibodies
PT3347054T (pt) Regimes de dosagem para conjugados fármaco-anticorpo anti-tf
GB2545674B (en) Dosing module
GB201510451D0 (en) Actuated-valve metering
GB201509907D0 (en) Antibodies
GB201418710D0 (en) Dosage regimen
GB201503438D0 (en) Antibodies
ZA201800217B (en) Novel dosage regimen tiacumicin compound
GB201516836D0 (en) Dosing regimen of combination
SI3139932T1 (sl) Režim zdravljenja za spojino tiacumicina
GB201720519D0 (en) Dosing regimen
GB201718106D0 (en) Dosing regimen
GB201718000D0 (en) Dosing regimen
GB201717694D0 (en) Dosing regimen
GB201609758D0 (en) Dosing Regimen
GB201521216D0 (en) Dosage regimen
GB201418708D0 (en) Dosage regimen
GB201400171D0 (en) Dosage regimen
GB201713609D0 (en) Packages
GB201514425D0 (en) Antibodies
GB201508437D0 (en) Antibodies
GB201508444D0 (en) Antibodies